Corporate earnings forecasts for the second quarter were lowered so much that companies are easily beating them.Market Insiderread more
The central bank is not normally in the business of easing into an economy that is showing few signs of a recession, generally holding fire until more pronounced signs of a...The Fedread more
His case for gold comes as central banks get more aggressive with policies that devalue currencies and are about to cause a "paradigm shift" in investing.Marketsread more
Challenging conditions in the U.S. housing market, along with tighter currency controls by the Chinese government, cause a stunning drop in foreign demand for American homes.Real Estateread more
House Speaker Nancy Pelosi says she wants her chamber to vote on a debt ceiling and budget deal by July 26.Politicsread more
Philips has acquired a start-up that texts you about your poop. That's Medumo, a Boston-based company, which works with hospitals to guide their patients through common...Technologyread more
The "'Cadillac tax," set to go into effect in 2022, is unpopular with both Republicans and Democrats, who say it punishes the middle class.Health and Scienceread more
Federal Judge William Pauley wrote in a court filing made public Wednesday that materials related to a campaign finance probe of Cohen should be unsealed — and denied a...Politicsread more
The U.S. economy continued growing at a "modest" rate in recent weeks, with consumers continuing to spend and a "generally positive" outlook overall even in the face of...Economyread more
CSX said it expects revenue to fall as much as 2% in 2019, well below a previous forecast of an increase of 1% to 2%.Marketsread more
Facebook's head of Calibra David Marcus is grilled during a House Financial Services Committee hearing over the company's digital currency plans.Technologyread more
Valeant Pharmaceuticals on Monday prepared to take its $53.8 billion takeover bid for Allergan directly to the Botox maker's shareholders, and ally Pershing Square called for a meeting to turn over the target company's board.
Pershing Square Chief Executive Officer Bill Ackman, whose hedge fund owns 9.7 percent of Allergan, said in a conference call with Valeant CEO Mike Pearson that he had requested a special meeting that could take place as early as Aug. 7. Allergan could also delay the meeting, where Pershing intends to replace a majority or more of the company's directors, to as late as November, Ackman said.
Pearson said Valeant expected in two to three weeks to file an exchange offer, a means of taking the bid to Allergan shareholders, with the U.S. Securities and Exchange Commission. He also urged Allergan to negotiate with Valeant.
"We are very committed to getting this deal done," he said.
Allergan officials were not immediately available for comment.
Laval, Quebec-based Valeant said on Friday that it would pay $72 in cash and 0.83 share of its stock for each Allergan share, increasing its offer for the second time last week.
Ackman said that after speaking with Allergan shareholders, he was scrapping plans for a non-binding referendum as a means of pressuring the company to negotiate.
Shares of Allergan were up 2.1 percent at $171.01 in early New York Stock Exchange trading. (Click here for the latest quote.) Valeant gained 0.3 percent to C$142.77 in Toronto, but its U.S.-listed shares dipped slightly. (Click here for the latest quote.)ast year.